FOLLOW US

MannKind Corp., advised by Cooley LLP, announced Monday it will acquire ScPharmaceuticals Inc., represented by Latham & Watkins LLP, in a $360 million deal that signals a bold leap into the cardiometabolic space.

Under the agreement, MannKind will purchase all outstanding shares of ScPharmaceuticals’ common stock at $6.35 per share in cash, a move that cements its ambition to diversify beyond its orphan lung portfolio.

Furoscix: A Key Driver Behind the Acquisition

ScPharmaceuticals is best known for its FDA-approved on-body infuser, Furoscix, designed to treat fluid overload in adults with chronic heart failure and kidney disease. The device offers an innovative, patient-friendly alternative to intravenous diuretics, making it a standout product in a field with growing demand.

“This transaction with MannKind represents an exciting next chapter for ScPharmaceuticals and the Furoscix brand,” said CEO John Tucker. “By combining our innovative products with MannKind’s proven commercial capabilities, we can accelerate patient access to essential therapies and create meaningful value for patients, providers, and shareholders.”

MannKind’s Expansion Strategy

The acquisition allows MannKind to establish a cardiometabolic division alongside its existing orphan lung business, providing new revenue drivers and long-term growth potential.

“This acquisition expands our patient-centered brands and underscores our dedication to advancing therapies for cardiometabolic and orphan lung diseases,” said MannKind CEO Michael Castagna. “With multiple product launches and new indications ahead, we are confident in our ability to accelerate double-digit growth over the next decade.”

To back the deal, MannKind has leaned on its financial partnership with Blackstone, recently securing an additional $175 million through an amended financing agreement. This builds on an August announcement of up to $500 million in non-dilutive capital to support MannKind’s growth initiatives.

Closing Timeline and Legal Teams

The transaction is expected to close in the fourth quarter of 2025, pending regulatory approval and customary closing conditions.

• MannKind: Advised by Cooley LLP, with partners Rowook Park and Mischi a Marca leading the team.

• ScPharmaceuticals: Advised by Latham & Watkins LLP, though full counsel details were not available Monday.

If approved, the deal will not only diversify MannKind’s pipeline but also position the company as a rising force in cardiorenal innovation—staking a $360 million claim on the future of patient-focused biopharmaceutical care.